Healthcare
•1072 stocks
•
Total Market Cap: Loading...
Market Cap Distribution
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (1072)
%
| Company | Market Cap | Price |
|---|---|---|
|
Penumbra's core products are endovascular vascular intervention devices (thrombectomy systems, catheters, and embolization coils).
|
$10.09B |
$260.49
+0.14%
|
|
Ensign delivers post-acute healthcare services including skilled nursing, senior living, and rehabilitative care, aligning with hospital/healthcare services themes.
|
$10.08B |
$175.34
-0.59%
|
|
BioMarin focuses on rare genetic disorders and enzyme therapies, aligning with the rare-disease biotech investment theme.
|
$10.03B |
$52.32
-3.40%
|
|
Diagnostics-related products/services including diagnostic instruments and software.
|
$9.91B |
$84.06
+0.79%
|
|
OTC pain relief products are a product category Albertsons offers in-store.
|
$9.86B |
$17.12
-1.10%
|
|
Vaccines are a key product line in Elanco's portfolio (pet and farm vaccines mentioned).
|
$9.74B |
$19.61
+3.59%
|
|
Rezdiffra is an oral, liver-directed small-molecule therapeutic, which is Madrigal's core product.
|
$9.54B |
$429.60
+0.21%
|
|
Remote patient monitoring via connected dialysis cyclers is part of care delivery.
|
$9.36B |
$123.99
-2.28%
|
|
DCI's Life Sciences activities include manufacturing-grade IsoTag AAV reagent for GMP bioprocessing, a concrete product line.
|
$9.31B |
$79.88
-2.06%
|
|
Align directly designs and sells dental devices (Invisalign aligners, mandibular advancement tools, palate expanders) which fall under the Dental Equipment category.
|
$9.12B |
$125.79
-2.26%
|
|
Verona Pharma operates as a pharmaceutical company with a commercial COPD therapy, aligning with the Large Cap Pharma category.
|
$9.10B |
$106.91
|
|
Nova sells diagnostic/measurement instruments as part of its metrology platforms.
|
$8.80B |
$302.28
-6.22%
|
|
Bio-Techne's automated diagnostic platforms and instruments (e.g., COMET, Simple Western) are core offerings sold under Diagnostic Equipment.
|
$8.72B |
$55.63
+6.51%
|
|
Aptar's core offering is drug delivery platforms, including nose-to-brain and inhaled delivery systems (e.g., Precision Nasal 3, Quotri DPIs).
|
$8.65B |
$130.93
-0.01%
|
|
Regencell's core focus is the development of neuropsychiatric therapeutics (ADHD/ASD) using proprietary formulations, clearly fitting neuropsychiatric drug development.
|
$8.31B |
$16.81
-8.54%
|
|
AYVAKIT and the pipeline assets are oral small-molecule therapeutics targeting KIT, making 'Oral Small Molecule Therapeutics' a core product category.
|
$8.27B |
$129.46
|
|
Bio-Rad develops and markets diagnostic instruments and platforms, including PCR-based systems used in diagnostics.
|
$8.10B |
$284.88
|
|
Jazz is a large-cap pharma company with a diversified revenue base and pipeline.
|
$7.99B |
$129.59
-0.16%
|
|
Core product category: Liquid biopsy testing platform used for cancer detection, MRD monitoring, and early screening.
|
$7.96B |
$64.22
-3.53%
|
|
Revolution Medicines focuses on oncology with a pipeline of RAS(ON) inhibitors and has clinically advanced small-molecule cancer therapies (e.g., daraxonrasib, elironrasib, zoldonrasib).
|
$7.92B |
$42.51
-1.41%
|
|
Halozyme's ENHANZE subcutaneous drug-delivery platform enables oncology therapeutics with rapid, high-volume subcutaneous administration and royalties from major cancer products.
|
$7.90B |
$64.10
-2.20%
|
|
Corcept's portfolio centers on oral small-molecule therapies (Korlym and relacorilant) targeting cortisol pathways.
|
$7.84B |
$73.96
-15.51%
|
|
Masimo's core offerings are noninvasive patient monitoring devices and systems, which define its main revenue through ongoing monitoring solutions.
|
$7.84B |
$144.64
-4.29%
|
|
Bio-Rad markets diagnostic instruments and related equipment used in clinical labs and research settings.
|
$7.73B |
$284.07
-0.50%
|
|
Directly manufactures or distributes dental equipment and related products used in dental practices.
|
$7.69B |
$63.17
-2.35%
|
|
Orthopedic devices portfolio including spine implants, trauma hardware, and joint systems.
|
$7.66B |
$56.57
-5.32%
|
|
CRL's core business is Contract Research Organization services providing preclinical testing, discovery, and development support for pharma/biotech.
|
$7.38B |
$146.07
-2.26%
|
|
The company produces safety syringes as part of its high-value syringe offerings.
|
$7.22B |
$23.85
-0.58%
|
|
Cytokinetics' lead and pipeline programs are focused on cardiovascular conditions (HCM, HFrEF, HFpEF), aligning with the Cardiovascular Drugs investable theme.
|
$7.17B |
$60.04
-0.38%
|
|
MSA markets and sells diagnostic equipment, including gas detectors and related monitoring devices.
|
$6.70B |
$170.57
-0.17%
|
|
Adesis provides contract research services as a core external-facing offering (contract research organization).
|
$6.53B |
$137.40
-3.36%
|
|
Rhythm's lead therapy IMCIVREE targets rare neuroendocrine diseases (MC4R pathway deficiencies) and the company is expanding into hypothalamic obesity, a rare disease indication.
|
$6.41B |
$100.82
+1.04%
|
|
Grifols operates as a large-cap pharmaceutical company with a primary focus on plasma-derived therapies and related immunology products.
|
$6.41B |
$9.32
-1.58%
|
|
CRISPR Therapeutics' core business is gene-editing therapies (ex vivo CASGEVY) and related gene-editing platforms.
|
$6.31B |
$73.07
-5.51%
|
|
VITAS Hospice provides hospital-style healthcare services (palliative/hospice care), aligning with the Hospital Services investable theme.
|
$6.29B |
$430.02
-0.50%
|
|
Auvelity, Sunosi, Symbravo and pipeline candidates are oral small-molecule therapeutics.
|
$5.99B |
$121.71
-0.66%
|
|
Abivax's lead drug obefazimod is an oral small-molecule therapeutic targeting inflammatory bowel disease.
|
$5.90B |
$93.77
+0.06%
|
|
Nuvalent is a clinical-stage oncology biotech focused on developing targeted cancer therapies, aligning with Biotech - Oncology.
|
$5.84B |
$81.39
+4.24%
|
|
Core commercial product: BCMA-directed autologous CAR-T cell therapy (CARVYKTI) and the company's cell therapy platform.
|
$5.82B |
$31.70
-1.22%
|
|
New healthcare/biometrics platform via recent acquisitions (medical devices and iris biometrics).
|
$5.76B |
$25.63
-2.47%
|
|
Core business is developing vaccines, including lead pneumococcal conjugate vaccines (VAX-24, VAX-31) and a platform enabling broader serotype coverage.
|
$5.64B |
$43.70
+3.75%
|
|
Core product is a patch-based cardiac monitoring device (Cardiology Devices).
|
$5.63B |
$176.20
-1.06%
|
|
Metsera's core focus is developing peptide-based obesity/metabolic therapies delivered via injectable and oral routes, under proprietary platforms (MINT, HALO, MOMENTUM), qualifying as a peptide therapeutics investable theme.
|
$5.55B |
$52.87
+0.84%
|
|
Doble diagnostic testing instruments align with ESCO's USG segment's diagnostic equipment offerings.
|
$5.45B |
$210.07
-0.42%
|
|
Company's focus on immunomodulatory inflammatory diseases (psoriasis, UC) via peptide therapeutics aligns with Immunology Therapeutics.
|
$5.39B |
$87.00
+29.10%
|
|
Mirion manufactures diagnostic equipment including radiation detection and measurement devices.
|
$5.36B |
$23.12
-1.53%
|
|
BRIUMVI is a monoclonal antibody therapeutic (anti-CD20) approved for relapsing MS, representing TG Therapeutics' flagship product.
|
$5.36B |
$33.76
-3.16%
|
|
Bruker sells diagnostic-grade instrumentation and analytical systems used in clinical/research diagnostics.
|
$5.35B |
$35.28
-2.54%
|
|
RadNet's core business is outpatient diagnostic imaging services across MRI, CT, PET, mammography, and ultrasound, i.e., medical imaging services.
|
$5.30B |
$70.60
-3.30%
|
|
Titan SGS stapler and Barrigel rectal spacer are clearly surgical devices used in operating rooms or procedural settings.
|
$5.28B |
$119.42
-4.53%
|
|
Sephience (PKU) and other PTC oral small molecule programs (vatiquinone, PTC518) are directly developed and commercialized as oral small molecule therapeutics.
|
$5.25B |
$66.23
+0.23%
|
|
Krystal's HSV-1 gene therapy platform and lead product VYJUVEK are gene therapies targeting rare diseases.
|
$5.24B |
$181.47
-4.43%
|
|
Avidity's platform delivers oligonucleotide therapeutics using antibody targeting (AOC), directly making oligonucleotide therapeutics.
|
$5.18B |
$42.95
+3.74%
|
|
Alkermes operates as a large-cap pharma company with a focused neuroscience/biopharmaceutical portfolio.
|
$5.15B |
$31.21
-0.54%
|
|
BLCO's MIEBO and XIIDRA are ophthalmic drugs targeting dry eye disease and associated inflammation, directly aligning with ophthalmic therapeutics.
|
$5.06B |
$14.32
-1.45%
|
|
Direct product category: Arrowhead's core TRiM RNAi therapeutics platform and pipeline drive its value.
|
$4.89B |
$35.41
-1.64%
|
|
Glaukos directly develops and sells ophthalmic drugs (iDose TR, Photrexa, Epioxa) for glaucoma and corneal health, representing core pharmaceutical offerings.
|
$4.72B |
$82.56
-5.10%
|
|
Core oncology biotechnology company focused on multispecific antibody therapeutics (BIZENGRI and petosemtamab) used for cancer.
|
$4.71B |
$69.05
+1.40%
|
|
Produces diagnostic and measurement equipment used in laboratory and industrial settings as part of its precision instrumentation portfolio.
|
$4.71B |
$41.42
-5.11%
|
|
Wrappersody vascular endoprosthesis and related vascular intervention devices are core Merit Medical products.
|
$4.67B |
$78.99
-3.99%
|
|
AMI provides compositional analysis instrumentation, aligning with diagnostic equipment in analytical instrumentation.
|
$4.53B |
$215.12
-2.93%
|
|
Directly develops cell therapies (CAR-T) and related platforms (ddCAR, ARC-SparX), which are Arcellx's core product offerings.
|
$4.52B |
$82.10
+3.69%
|
|
Pharmaceuticals & Biotechnology focus (Qsiva product) within the Pharma segment.
|
$4.48B |
$8.28
+1.10%
|
|
Nelson Labs provides outsourced laboratory testing and advisory services, a core service line.
|
$4.36B |
$15.35
-2.66%
|
|
Directly tied to Akero's lead product candidate EFX being developed as a ready-to-use pre-filled syringe formulation for administration.
|
$4.30B |
$53.88
-0.39%
|
|
The company develops oral, nonpeptide small molecule therapeutics (e.g., paltusotine) for endocrine GPCR targets.
|
$4.08B |
$42.32
-2.74%
|
|
Oral small molecule therapeutics: Kymera aims to deliver biologics-like efficacy with oral dosing, representing a major product class.
|
$4.00B |
$56.00
+1.49%
|
|
Healthcare division includes patient monitoring platforms and related devices/services.
|
$3.98B |
$236.79
-0.53%
|
|
VK2735 is a peptide-based therapeutic (dual GLP-1/GIP receptor agonist), placing it squarely in the Peptide Therapeutics category.
|
$3.77B |
$33.56
-6.13%
|
|
SMA is a rare disease and Scholar Rock's lead program apitegromab targets this indication.
|
$3.75B |
$39.46
-3.94%
|
|
Radium radiopharmaceutical isotopes development (TAT) using Mill streams; potential commercial isotope production.
|
$3.74B |
$16.71
-4.57%
|
|
ADMA's core offerings are plasma-derived immunoglobulin therapies (ASCENIV, BIVIGAM, Nabi-HB) for immune deficiencies, aligning with Immunology Therapeutics.
|
$3.73B |
$15.61
+1.17%
|
|
Lantheus markets imaging agents used in PET and ultrasound (e.g., PYLARIFY and DEFINITY), a core medical imaging product line.
|
$3.68B |
$53.23
+2.54%
|
|
Mirum's core business is focused on rare diseases with approved medicines and a pipeline targeting orphan conditions (CTX, PFIC/ALGS, PSC/PBC).
|
$3.64B |
$73.57
-0.65%
|
|
OCS provides real-time patient/organ monitoring data during ex vivo perfusion.
|
$3.63B |
$107.29
-5.50%
|
|
Healthcare/Life Sciences supports medical device components manufacturing and subassemblies.
|
$3.62B |
$133.69
-9.20%
|
|
Next-generation insufflators and endoscopic pumps indicate direct medical-surgical equipment offerings.
|
$3.60B |
$99.96
-5.25%
|
|
Integer is a contract development and manufacturing organization for medical devices, providing outsourced development and manufacturing services to OEMs.
|
$3.53B |
$101.05
-1.93%
|
|
ACADIA develops CNS/neuropsychiatric therapeutics, including NUPLAZID for PDP and DAYBUE for Rett syndrome, positioning it in neuropsychiatric drug development.
|
$3.52B |
$21.05
-0.94%
|
|
Oral Small Molecule Therapeutics: SpringWorks' approved assets OGSIVEO and GOMEKLI are oral, small-molecule targeted therapies forming the core revenue streams.
|
$3.52B |
$46.99
|
|
Biotech - Rare Diseases: company focusing on rare disease diagnostics and data assets.
|
$3.47B |
$121.72
-4.53%
|
|
Laser-based medical devices used in surgical/medical settings position IPG within Surgical Equipment.
|
$3.43B |
$80.68
-7.23%
|
|
Zai Lab's portfolio and late-stage pipeline are heavily oncology-focused with potential blockbusters and China/global development.
|
$3.43B |
$31.62
+0.86%
|
|
Ligand's Captisol and NITRICIL platforms are proprietary drug-delivery technologies that Ligand licenses to partners, representing a direct product/platform offering.
|
$3.43B |
$177.73
-2.16%
|
|
Obicetrapib is an oral small-molecule therapeutic candidate developed by NewAmsterdam Pharma, representing the core product category.
|
$3.42B |
$37.05
+10.86%
|
|
Telix's core offering includes radioligand therapies using radiopharmaceuticals for cancer (alpha-emitter and related therapies).
|
$3.35B |
$10.00
|
|
Amedisys provides home health, hospice, and high-acuity in-home care services, aligning with hospital/services provider themes.
|
$3.31B |
$100.99
+0.01%
|
|
Directly develops oncology-focused biologic/cancer therapy (cretostimogene) used to treat bladder cancer.
|
$3.30B |
$43.25
-3.74%
|
|
Indivior is a global pharmaceutical company with core revenue from SUBLOCADE and related OUD therapies, fitting the Large Cap Pharma category.
|
$3.28B |
$23.78
-1.53%
|
|
Soleno's VYKAT XR is an oral small-molecule therapeutic targeted at hyperphagia in Prader-Willi Syndrome.
|
$3.27B |
$62.72
-1.74%
|
|
Nobel Biocare premium implants, Alpha-Bio, and Implant Direct are prosthetics/implants products.
|
$3.23B |
$19.06
-4.94%
|
|
HUTCHMED directly develops and sells oral, small-molecule targeted therapeutics across oncology and immunology indications.
|
$3.15B |
$3.66
|
|
Core business: Amneal's primary revenue driver is generic medicine manufacturing (Affordable Medicines).
|
$3.12B |
$9.97
-3.11%
|
|
Xenon’s portfolio centers on oral small‑molecule CNS therapeutics (Kv7 opener XEN1101 and related programs) with epilepsy and neuropsychiatric expansion.
|
$3.04B |
$39.64
-4.34%
|
|
PBH's flagship eye-care products (e.g., Clear Eyes) are ophthalmic drugs, making Ophthalmic Drugs a direct product category.
|
$3.01B |
$61.00
-2.80%
|
|
uniQure directly develops AAV-based gene therapies and its proprietary miQURE silencing technology, which are the core products/services it provides.
|
$3.01B |
$54.50
-2.45%
|
|
ICU Medical’s core products are medical devices and equipment (infusion pumps, hazardous-drug handling systems).
|
$3.01B |
$119.67
-0.24%
|
|
Centessa is advancing oncology-focused therapies via the LockBody platform.
|
$2.98B |
$22.31
-2.75%
|
|
Directly develops and commercializes gene therapies using AAV vectors for rare diseases, covering programs like UX111, DTX401, UX701, UX143, and GTX-102.
|
$2.97B |
$31.45
-1.13%
|
|
XDEMVY is an ophthalmic drug (lotilaner ophthalmic solution 0.25%) and the company's flagship product, establishing a major ophthalmic drug category.
|
$2.95B |
$70.14
-0.09%
|
Showing page 2 of 11 (1072 total stocks)
Loading industry metrics...
Loading comparison data...
